# Evaluation of CYP2C9 Activity

> **NCT00162461** · NA · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 1200 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Phenytoin single dose (300 mg)

## Key facts

- **NCT ID:** NCT00162461
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1998-08
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 1200 (ESTIMATED)
- **Last updated:** 2018-06-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00162461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00162461, "Evaluation of CYP2C9 Activity". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00162461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*